Pharmaceuticals · ARBP
Pharma - Formulators
from 1,589 today
Aurobindo reported strong Q1FY27 financial performance with revenue rising 16.3% YoY and 3.4% QoQ to Rs 9,150 Cr, driven by broad-based traction across key business areas including US and Europe formulations. Operational profitability and margins expanded supported by favorable business mix and operational efficiencies, leading to a rating revision from BUY to HOLD with a target price of Rs 1,600.
Aurobindo Pharma reported Q1FY27 adjusted EBITDA of INR 19.2bn, up 20% YoY, beating estimates, and maintained its 21% OPM guidance for FY27E. We retain our 'Hold' rating with a revised target price of INR 1,600/share, valuing the stock at 18x FY28E EPS.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
